secwatch.observer — SEC 8-K summary
======================================

Issuer:     STANDARD BIOTOOLS INC. (LAB)
CIK:        0001162194
Form:       8-K
Filed at:   2026-08-05T20:10:20+00:00
Accession:  0001193125-26-335106
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Standard BioTools Q2 revenue $20.1M, down 7.6% YoY; adjusted EBITDA improves 84%
--------------------------------------------------------------------------------

- Revenue $20.1M, down 7.6% YoY; consumables $9.4M (-10%), instruments $5.1M (-2%), services $5.6M (-8%).
- Net loss from continuing ops $21.5M vs $17.7M; operating loss $25.4M vs $25.7M.
- Adjusted EBITDA loss $2.5M, improvement of $13.6M or 84% YoY.
- Merger with Treeline Biosciences progressing; stockholder vote expected before year-end 2026.
- Withdrew full year 2026 revenue outlook due to pending merger.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1162194/000119312526335106/0001193125-26-335106-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1162194/000119312526335106/lab-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-335106

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer